Proposed metabolic pathways of ACT-1004-1239 in humans. | Download Scientific Diagram
ACT-1004-1239 - Drug Hunter
![ACT-1004-1239 [2178049-58-4] CXCR7 Antagonist | Glixxlabs.com High Quality Supplier](http://www.glixxlabs.com//S20/GLXC-23387.png "ACT-1004-1239 [2178049-58-4] CXCR7 Antagonist | Glixxlabs.com High Quality Supplier")
ACT-1004-1239 [2178049-58-4] CXCR7 Antagonist | Glixxlabs.com High Quality Supplier
Effects of Small Molecule Ligands on ACKR3 Receptors | Molecular Pharmacology
Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT- 1004-1239 | Journal of Medicinal Chemistry
Project Overview
Scientific Update on Twitter: "Dr Gabriel Schafer @Idorsia opening day 2 of our conference in Basel talking about development of a stereoselective route for CXR7 antagonist ACT-1004-1239 #OPRDEU22 https://t.co/GmjonCOCgr" / Twitter
ACT-1004-1239 treatment significantly reduces CNS inflammation,... | Download Scientific Diagram
Frontiers | Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data
Preclinical development of ACT-1004-1239, a potent and selective CXCR7/ACKR3 antagonist in multiple sclerosis treatment
ACT-1004-1239 treatment significantly reduces CNS inflammation,... | Download Scientific Diagram
Treatment with ACT-1004-1239 dose-dependently increases plasma CXCL11... | Download Scientific Diagram
Preclinical development of ACT-1004-1239, a potent and selective CXCR7/ACKR3 antagonist in multiple sclerosis treatment
Idorsia: Heading Towards Profitability Faster Than Expected (OTCMKTS:IDRSF) | Seeking Alpha
Frontiers | Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data
2178049-58-4 | ACT-1004-1239| ACT1004-1239; ACT 1004-1239; ACT-10041239; ACT -1004 1239; ACT10041239; ACT 1004 1239|BioChemPartner
ACT-1004-1239 |2178049-58-4 |Chemokine Receptor (CCR and CXCR)|HmoBio.com
December Archives - Drug Hunter
Idorsia erhält wichtige Zulassung | Finanz und Wirtschaft
ACT-1004-1239 | CXCR Antagonist | MedChemExpress
Reaction pathways at the initial steps of trioxane polymerisation - Catalysis Science & Technology (RSC Publishing) DOI:10.1039/C8CY01691G
ACT-1004-1239 and CXCL12 plasma concentration-time profiles and... | Download Scientific Diagram
Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT- 1004-1239 | Journal of Medicinal Chemistry
